Immunoassays used for routine drug of abuse (DOA) and toxicology screening may be limited by cross-reacting compounds able to bind to the antibodies in a manner similar to the target molecule(s). To date, there has been little systematic investigation using computational tools to predict cross-reactive compounds.
may also have value in focusing cross-reactivity testing on compounds with high similarity to the target molecule(s) and limiting testing of compounds with low similarity and very low probability of cross-reacting with the assay. Immunoassays are widely used for detection of drugs and drug metabolites (1 ) . A common application is drug of abuse/toxicology (DOA/Tox) 8 screening performed on urine and other body fluids (2 ) . The use of immunoassays as screening tests is distinguished from confirmation methods such as GC-MS and liquid chromatography-tandem mass spectrometry, which can provide definitive identification of drugs and their metabolites. Positive DOA/Tox immunoassay screening results are often designated as "preliminary", "presumptive", or "unconfirmed" positives (2 ) . One limitation of immunoassays is interference caused by compounds with structural similarity to the target molecule(s) of the assay (i.e., typically one or more haptens against which the assay antibodies were generated) (3 ) . Such cross-reactive molecules can be structurally related drugs, drug metabolites, or endogenous compounds. During the development of commercially marketed immunoassays, manufacturers typically test common drugs for cross-reactivity as well as endogenous compounds (4 ) .
DOA/Tox screening assays may have broad specificity toward classes of drugs such as amphetamines, barbiturates, benzodiazepines, cannabinoids, and opiates. Other DOA/Tox screening assays are directed toward detection of a single target drug or metabolite (e.g., buprenorphine, benzoylecgonine). There are ad-vantages to using DOA/Tox screening assays with broad specificity. First, for some classes of drugs, the management of an overdose involves the same treatment regardless of which particular drug within the class is involved (e.g., flumazenil as an antidote for benzodiazepine overdose). Second, using a single assay to screen for multiple drugs within a class is less expensive than using separate assays for each individual drug.
Although package inserts and manufacturers' documents collectively contain extensive data on assay cross-reactivity, during the last several decades many reports of cross-reactivity have been released after assay marketing. Examples of published reports of DOA/Tox assay cross-reactivity include fluoroquinolone antibiotic cross-reactivity with opiates assays (5, 6 ) , quetiapine cross-reactivity with tricyclic antidepressant (TCA) assays (7) (8) (9) , fentanyl cross-reactivity with lysergic acid diethylamide (LSD) immunoassays (10, 11 ) , sertraline and sertraline metabolite cross-reactivity with benzodiazepine assays (12, 13 ) , and venlafaxine and O-desmethylvenlafaxine cross-reactivity with phencyclidine (PCP) assays (14 ) .
To date there has been no comprehensive computational analysis aimed at predicting cross-reactivity of DOA/Tox screening assays. Our hypothesis was that a given compound is more likely to cross-react with an immunoassay if the compound shares a high level of structural similarity to the target molecule(s) of the assay.
We used an in silico method known as similarity analysis, which determines the similarity between molecules independent of any in vitro data (15) (16) (17) . Similarity can be assessed at the 1-dimensional, 2-dimensional (2D), and 3-dimensional (3D) levels (17) (18) (19) (20) . Common 2D-similarity approaches employ fragment bit strings compared by use of the Tanimoto coefficient (0 being maximally dissimilar, 1 being maximally similar). 3D-similarity methods essentially require the development of a pharmacophore pattern that represents the arrangement of the chemical features and distances between them that are important for biological activity (21 ) .
In this study, we applied similarity analyses to a wide range of marketed immunoassays used for DOA/ Tox screening. The overall goal was to develop computational methods that efficiently predict compounds likely to cross-react with immunoassays.
Materials and Methods

STANDARDS AND REAGENTS
Quetiapine fumarate and escitalopram oxalate were obtained from Sequoia Research Products. Citalopram hydrobromide was purchased from Molcan. All other drugs were obtained from Sigma.
CLASSIFICATION OF IMMUNOASSAY CROSS-REACTIVITY DATA
Cross-reactivity data were obtained from manufacturers' package inserts or supplemental manufacturers' documents. (See Data Supplement 1 that accompanies the online version of this report at http://www.clinchem. org/content/vol55/issue6). This information is often presented as the concentration of the tested compound that produces the same response in the assay as the cutoff concentration of the target compound, or occasionally as percentage cross-reactivity. Additional data were obtained from the peer-reviewed literature for cannabinoid (22 ) , opiate (5, 6 ) , and TCA assays (23, 24 ) .
To classify cross-reactivity of compounds for the various assays, we broadly divided compounds into "strong true positives", "weak true positives", "strong false positives", "weak false positives", "true negatives", and "false negatives" (Table 1) . For any compound, meeting the criteria for strong or weak cross-reactivity in any 1 assay was sufficient for classification in that category. Within-class compounds were formally defined as drugs and their metabolites (if present) whose detection allowed for the interpretation that 1 or more members of the target drug class were present in the sample. For example, for benzodiazepines, within-class compounds include alprazolam, chlordiazepoxide, clonazepam, diazepam, and their metabolites but not the therapeutically similar but nonbenzodiazepine drugs eszopiclone and zolpidem.
SIMILARITY SEARCHING IN DISCOVERY STUDIO 2.0
Similarity searching used the "find similar molecules by fingerprints" protocol in Discovery Studio 2.0 (a gift from Accelrys, San Diego, CA). The mapping description language (MDL) public keys and long-range functional class fingerprint description 6 keys (FCFP) (referred to as FCFP_6Ј) (25 ) were used separately with the Tanimoto similarity coefficient and an input query molecule (17 ) . It should be noted that these similarity algorithms do not recognize differences between stereoisomers and racemic mixtures (e.g., citalopram and escitalopram).
PHARMACOPHORE FINGERGRINTS
We calculated 3-point and 4-point pharmacophorebased fingerprints from the 3D conformation using the Molecular Operating Environment (Chemical Computing Group). Each atom in a molecule was given 1 of 8 atom types computed from 3 atomic properties ("in system", "is donor", and "is acceptor"). All quadruplets of atoms were coded as features using the interatomic distance, atom types, and chirality.
DATABASES
The main database searched was created using the database of US Food and Drug Administration-cleared drugs derived from the Clinician's Pocket Drug Reference (26 -28 ) ("SCUT 2008 database"). The database was supplemented with drugs of abuse and drug metabolites (n ϭ 110) important in clinical toxicology testing. The total database of 786 compounds was referred to as the "Expanded SCUT database".
CROSS-REACTIVITY TESTING
Tests for cross-reactivity were performed to determine the lowest concentration of a compound that when added to drug-free urine caused a reaction result that equaled or exceeded the cutoff concentration for the target compound of the assay (4 ). We performed crossreactivity testing according to manufacturers' instructions by using 2 different assay systems, Emit and Biosite: Emit ® II plus assays (amphetamines, barbiturate, benzodiazepine, cannabinoids, cocaine metabolite, methadone, opiate, phencyclidine, propoxyphene) and Emit tox™ serum (tricyclic antidepressants) run on Siemens (Dade-Behring) Viva-E analyzers and Biosite Triage® Tox screen.
Results
CLASSIFICATION OF CROSS-REACTIVITY DATA
We compiled cross-reactivity data for 84 marketed versions of 18 DOA/Tox screening assays [amphetamines, barbiturates, benzodiazepines, benzoylecgonine, buprenorphine, cannabinoids, cotinine, 6-acetylmorphine, LSD, 3,4-methylenedioxymethampetamine (Ecstasy), methadone, 2-ethylidine-1,5-dimethyl-3,3-diphenypyrrolidine, methaqualone, opiates, oxycodone, phencyclidine, propoxyphene, and TCAs] using information from package inserts, supplemental manufacturers' data, and 5 peer-reviewed articles (Data Supplement 1) (5, 6, (22) (23) (24) . Top prescribed medications in the US in 2007 (29) are also highlighted. Classificationofallavailablecross-reactivitydatayieldedatotalof1961 datapoints-162 strong true positives, 20 weak true positives, 20 strong false positives, 69 weak false positives, 1681 true negatives, and 9 false negatives. We then used 2 algorithms, MDL public keys and FCFP, to compute 2D similarity for the most common target compounds for the 18 immunoassay target compounds (d-amphetamine, secobarbital, diazepam, buprenorphine, 9-carboxy-11-nor-⌬ 9 -tetrahydrocannabinol, carisoprodol, benzoylecgonine, cotinine, 2-ethylidine-1,5-dimethyl-3,3-diphenypyrrolidine, 6-acetylmorphine, LSD, methadone, methaqualone, morphine, oxycodone, phencyclidine, propoxyphene, and desipramine) to compounds in the Expanded SCUT Database and, where applicable, to any additional compounds reported in the package inserts.
The similarity of desipramine (target compound of several TCA assays) to 5 compounds is shown in Fig.  1 . Desipramine has the highest similarity (in descending order) to clomipramine (another TCA), chlorpromazine (a phenothiazine antipsychotic), and quetiapine (another tricyclic). Desipramine has low similarity to secobarbital and essentially no 2D similarity to ibuprofen.
The data analysis is complicated for some DOA/ Tox screening assays in that the same target compound is not always used for all marketed versions (Data Supplement 1). This issue applies to amphetamine, benzodiazepine, and TCA assays. We chose d-amphetamine, diazepam, and desipramine as the target compounds for amphetamine, benzodiazepine, and TCA screening assays, respectively, for the total data comparisons. We also provide data obtained using alternative target Table 1 . Criteria for classifying cross-reactivity of compounds.
Classification Definition
DOA/Tox assays
Target compound For a given DOA/Tox assay, the drug or drug metabolite used as the antigenic (hapten) target (e.g., morphine for opiates assay)
Strong true positives Within-class compounds causing cross-reactivity equal to the positive cutoff of the assay at concentrations of less than 10 000 g/L Weak true positives Within-class compounds causing cross-reactivity equal to the positive cutoff of the assay at concentrations of 10 000 to 100 000 g/L Strong false positives Out-of-class compounds causing cross-reactivity equal to the positive cutoff of the assay at concentrations of less than 10 000 g/L Weak false positives Out-of-class compounds causing cross-reactivity equal to the positive cutoff of the assay at concentrations of 10 000 to 100 000 g/L
True negatives Out-of-class compounds causing no cross-reactivity or cross-reactivity equal to the positive cutoff of the assay only at concentrations of greater than 100 000 g/L False negatives Within-class compounds causing no cross-reactivity or cross-reactivity equal to the positive cutoff of the assay only at concentrations of greater than 100 000 g/L compounds (e.g., nordiazepam for benzodiazepines) in Data Supplement 2.
SIMILARITY COMPARISONS COMBINING DATA FROM ALL ASSAYS
Plotting of the similarity coefficients for all datapoints (Fig. 2) shows that MDL public keys are generally higher than those calculated using FCFP. However, for either method, the mean similarity [mean (SD)] is significantly higher (P Ͻ 0.001, unpaired t-test) using either MDL public keys or FCFP for strong true positives (Fig. 2) . With the use of MDL public keys, 45.6% of the strongly cross-reactive compounds (strong true positives and strong false positives) had similarity coefficients of 0.8 or higher relative to the target compound of the assay. For the true negatives, only 24 of 1681 (1.4%) of compounds had similarity coefficients of 0.8 or higher to the target compounds. Thus, a cutoff of 0.8 would have a positive predictive value of 77.6% in distinguishing compounds capable of strong crossreactivity from the true negatives. Conversely, 65.9% of true negatives have similarity coefficients of Ͻ0.4 to the target compounds whereas only 3 of 1681 (1.6%) of strongly cross-reactive compounds fit in this category. Strongly cross-reactive compounds with MDL public keys similarity of 0.5 or less to the target compound were found for only 5 DOA/Tox screening assays (amphetamines, benzodiazepines, methadone, PCP, and TCAs). These compounds accounted for only 14 of 182 (7.6%) of the total strongly cross- Using desipramine (target compound of some TCA screening assays) as the target compound, we calculated 2D similarity using MDL public keys and FCFP to 5 different compounds, 3 of which (clomipramine, chlorpromazine, quetiapine) are 3-ringed molecules and 2 of which (secobarbital, ibuprofen) have a single ring in their structures. Of the 5 test compounds, clomipramine (also a TCA) has the highest similarity to desipramine, and ibuprofen has the lowest similarity.
reactive compounds. Ten of the 14 examples came from the benzodiazepines assays (5 compounds) and TCA assays (5 compounds). In contrast, 1473 of 1681 (87.6%) of true negatives had similarity coefficients of 0.5 or less.
SIMILARITY COMPARISONS WITHIN INDIVIDUAL DOA/TOX SCREENING ASSAYS
Data obtained using MDL public keys for 4 broadspecificity assays (amphetamines, barbiturates, benzodiazepines, and TCAs) are shown in Fig. 3 . These data show the challenge in identifying weakly cross-reactive compounds for broadly specific assays, in that the similarity for weakly cross-reactive compounds can lead to overlap with that for true negatives. Data obtained using MDL public keys for cannabinoid, benzoylecgonine, opiate, and PCP assays are shown in Fig. 4 . For these 4 assays, all cross-reactive compounds (strong or weak) have similarity coefficients to the respective target compounds higher than the average similarity of all true negatives. For the opiate assays (Fig. 4C) , several fluoroquinolone antibiotics, identified in the literature as cross-reacting with some opiate screening assays (5, 6 ) , have similarity coefficients that overlap with those of the true negatives but are higher than the majority of compounds classified as true negatives. In addition, fentanyl has relatively high similarity (MDL, 0.621; FCFP, 0.152) to LSD, consistent with studies indicating cross-reactivity of fentanyl with LSD immunoassays (10, 11 ) . Plots for DOA/Tox screening assays not shown in Another way to examine the data is to analyze how the 2D structural similarity for the cross-reactive compounds relates to that for true negatives. With the use of MDL public keys data, the mean similarity for the true negatives (indicated as a dashed line in Figs. 3 and 4 and Supplemental Data Fig. 1 ) was lower than the similarity for nearly all cross-reactive compounds. The only exceptions were the assays for benzodiazepines (ketoprofen, lovastatin, and modafanil were weak false positives in 1 marketed assay each), propoxyphene (methaqualone was a weak false positive in 1 marketed assay), and TCAs (6 compounds were weak false positives in a single marketed assay). The similarity for true negatives overlapped more with cross-reactive compounds when we used FCFP, with 4 assays (benzodiazepine, opiate, propoxyphene, and TCA) having crossreactive compounds that had similarity coefficients lower than the average similarity for all true negatives. Consequently, with the use of MDL public keys or FCFP, strong true positives with similarity lower than the mean similarity coefficient for true negatives were rare.
The 2D similarity results suggest that the targets of DOA/Tox screening immunoassays can be categorized on a continuum based on whether they have low to high similarity to other compounds that can be encountered clinically. At one extreme would be benzo- ylecgonine, which has high similarity to cocaine and other cocaine metabolites, but low predicted similarity to other clinically encountered drugs (Fig. 4B) . These characteristics may explain why marketed benzoylecgonine screening immunoassays have very few documented cross-reacting substances. At the other extreme would be the TCA desipramine. There is substantial overlap between the similarity of despiramine to other TCAs and to other 3-ringed molecules such as cyclobenzaprine, phenothiazines, or quetiapine (Fig.   3D ), suggesting that cross-reactivity is likely to be a problem with TCA screening immunoassays no matter which TCA is chosen as the target.
We also explored 3D similarity classification approaches by using 3-or 4-point pharmacophore fingerprints. However, we found that even by varying cutoff settings, these algorithms were too restrictive and missed many cross-reactive compounds, including some strong true positives [e.g., the 4-point pharmacophore method assigned zero similarity to some Fig. 3 . Similarity of drugs and drug metabolites relative to the target compounds for four broadly specific DOA/Tox assays. Cross-reactivity data for 4 DOA/Tox assays were sorted into 6 categories. Plotted similarity data (obtained using MDL public keys and the Tanimoto coefficient) of each tested compound to the target compound of the DOA/Tox assay are shown. (A), Amphetamine assays (using d-amphetamine as the target); (B), barbiturate assays (using secobarbital as the target compound); (C), benzodiazepine assays (using diazepam as the target compound); (D), TCA assays (using desipramine as the target compound).
strong true positives (Supplemental Data Fig. 3 found in Data Supplement 2)].
CROSS-REACTIVITY TESTING GUIDED BY SIMILARITY
PREDICTIONS
As evidenced in published reports, some cross-reactive compounds are recognized after assays are marketed. We used similarity analyses to predict additional crossreactive compounds for 10 assays: amphetamine, barbiturate, benzodiazepine, benzoylecgonine, cannabinoid, methadone, opiate, PCP, propoxyphene, and TCA (Supplemental Data Fig. 4 in Data Supplement 2). We then tested 46 such compounds on 2 different platforms (Biosite Triage, Syva Emit assays on Siemens Viva-E analyzers), identifying additional cross-reactive compounds for amphetamines, barbiturates, opiates, PCP, and TCA assays ( Table 2) . Eight of the crossreactivities we identified have not, to our knowledge, yet been reported in the published literature or package inserts to cross-react with any marketed version of a particular DOA/Tox immunoassay ( Table 2 ). These 8 new cross-reactivities were: atropine (Biosite Triage   Fig. 4 . Similarity of drugs and drug metabolites relative to the target compounds for 4 DOA/Tox assays. Cross-reactivity data for 4 DOA/Tox assays were sorted into 6 categories. Plotted similarity data (obtained using MDL public keys and the Tanimoto coefficient) of each tested compound to the target compound of the DOA/Tox assay of the DOA/Tox assay are shown. (A), Cannabinoid assays (using 9-carboxy-11-nor-⌬ 9 -tetrahydrocannabinol as the target compound); (B), cocaine metabolite (benzoylecgonine) assays; (C) opiate assays (using morphine as the target compound); (D) phencyclidine assays. Cross-reactivity positives opiates assay), citalopram (Syva Emit TCA assay), dextromethorphan (Syva Emit opiates and propoxyphene assays), escitalopram (Syva Emit TCA assay), mirtazapine (Syva Emit TCA assay), oxcarbazepine (Biosite Triage barbiturates assay), and selegiline (Syva Emit amphetamines assay). Cetirizine was previously identified as cross-reacting with fluorescence polarization immunoassays (30 ) . Quetiapine was previously identified as cross-reacting with some marketed TCA screening immunoassays (7) (8) (9) .
SIMILARITY-BASED PREDICTIONS FOR ASSAYS IN DEVELOPMENT
There are at least 4 other drugs with potential abuse liability for which immunoassays are in development: carisoprodol, fentanyl, ketamine, and meperidine. We calculated similarity of these 4 drugs to the compounds in the Expanded SCUT database (Data Supplement 1). Carisoprodol showed high similarity to its active metabolite meprobamate ( 
Discussion
Cross-reactivity between structurally related compounds remains a challenge in the design and clinical use of DOA/Tox screening immunoassays (3 ) . In this study we applied similarity analysis as a new tool to classify compounds that are likely to cross-react with common DOA/Tox screening tests. Using our predictions, we performed cross-reactivity testing and identified 8 assay cross-reativities not previously reported. Of the 3 molecular descriptors evaluated, MDL public keys were shown to be the most useful for this purpose. The similarity coefficients generated by the MDL analysis were well distributed with clear separation (on average) between cross-reactive compounds and those that do not cross-react. FCFP and pharmacophore fingerprints were best suited for identifying very close structural analogs but not compounds with lower degrees of similarity. There are other molecular fingerprints that could be evaluated in the future (31 ) .
There are several screening strategies that could be employed using the techniques we report in this study. One approach is to test all clinically relevant compounds with similarity coefficients of 0.8 or higher to the target compound and avoid any testing of those with a coefficient of 0.4 or less. For compounds with similarity coefficients between 0.4 and 0.8, additional selection criteria could be used such as pharmacokinetics and frequency of overdoses.
A limitation of the similarity approaches is that these cannot account for the complex 3D molecular interactions inherent in antibody-antigen binding. To our knowledge, the 3D structure of an antibody used in a DOA/Tox screening assay and its antigen target has not been reported, although there has been structural determination of antibodies being evaluated as novel antidotes to DOA overdose (e.g., PCP (32 ) and cocaine (33, 34 ) , in which the antibody interacts with all portions of the target molecule). For DOA/Tox screening assays in which similar antibody-drug interactions apply, whole-molecule similarity measures (as used in this study) seem appropriate for prediction. However, a crystal structure of morphine bound to a monoclonal antibody showed the antibody interacting with the more hydrophobic portion of morphine, whereas the hydrophilic half was mostly exposed to solvent (35 ) . The crystal structure of digoxin with a Fab fragment revealed the carbohydrate portions of the drug unbound by antibody and exposed to solvent (36 ) . For target compounds like these, similarity searching using substructures may be worth evaluating.
An additional limitation of the similarity methods used in this study is that these do not account for the concentration dependence of cross-reactivity. For instance, a substance with poor cross-reactivity may be problematic if present in serum/plasma or urine at much greater concentrations than the analyte. This is likely to especially be an issue for drugs used in low doses, resulting in low concentrations in body fluids. The synthetic opioid fentanyl would be an example of such a drug. For a drug such as fentanyl, a wider range of similarities may need to be considered in testing potentially cross-reactive substances.
A final consideration is that biological specimens may contain several cross-reacting substances. The situation can be quite complex for classes of drugs such as benzodiazepines that have multiple metabolites. Total cross-reactivity to a DOA/Tox immunoassay can be derived from multiple compounds, each cross-reacting to varying degrees. Future studies can be directed at predicting such total cross-reactivity by extensions of the similarity methods used in this study.
False-positive DOA/Tox screening results present a challenge for clinical chemists and clinicians because emergency departments, substance abuse treatment programs, transplant programs, pain clinics, and other treatment settings use these assays. Clinicians may use the results for a variety of decisions including administering antidotes, prescribing narcotic medications, and determining whether to proceed with or delay elective surgeries. Clinical chemists may be consulted as to the likely cause of an unexpectedly positive screening assay. The extensive similarity calculations we performed (summarized in the Data Supplement 1) highlight drugs or metabolites that have high similarity to the assay target antigen(s) but whose cross-reactivity has not been reported. These data can aid clinical chemists in determining what drugs or metabolites may contribute to assay positivity unexplained by known assay cross-reactivities, clinical history, or confirmatory testing. The similarity tools also provide a rational framework for manufacturers and regulators to focus crossreactivity testing on drugs or metabolites most likely to cross-react.
